Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

NCT07497607 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Oropharyngeal Squamous Cell Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG: Cisplatin
RADIATION: Radiotherapy

Sponsor

Sara Medek